Insider Trading Activity For Insys Therapeutics, Inc. (NASDAQ:INSY)
Saeed Motahari , CEO of Insys Therapeutics, Inc. (NASDAQ:INSY) reportedly Bought 5,500 shares of the company’s stock at an average price of 8.92 for a total transaction amount of $49,060.00 SEC Form
Insider Trading History For Insys Therapeutics, Inc. (NASDAQ:INSY)
Analyst Ratings For Insys Therapeutics, Inc. (NASDAQ:INSY)
These are 2 Hold Ratings, 2 Buy Ratings .
The current consensus rating for Insys Therapeutics, Inc. (NASDAQ:INSY) is Buy (Score: 2.50) with a consensus target price of $12.67 , a potential (39.81% upside)
Analyst Ratings History For Insys Therapeutics, Inc. (NASDAQ:INSY)
- On 3/9/2016 JMP Securities Lower Price Target of rating Market Outperform with a price target of $38.00 to $30.00
- On 4/14/2016 Janney Montgomery Scott Initiated Coverage of rating Buy with a price target of $22.00
- On 6/9/2017 Jefferies Group LLC Reiterated Rating Buy with a price target of $14.00
- On 7/26/2017 Piper Jaffray Companies Set Price Target of rating Hold with a price target of $10.00
- On 8/3/2017 Oppenheimer Holdings, Inc. Reiterated Rating Hold
- On 8/4/2017 Royal Bank Of Canada Lower Price Target of rating Outperform to Outperform with a price target of $16.00 to $14.00
Recent Trading Activity for Insys Therapeutics, Inc. (NASDAQ:INSY)
Shares of Insys Therapeutics, Inc. closed the previous trading session at 9.06 down -0.01 -0.11% with 750,235 shares trading hands.